Fonseca SL¹, Early PJ¹*, Mancini SL^1,2, Slater BM³, Olby NJ¹, Mariani CL¹, Munana KR¹, Zhong Li⁴ and Messenger KM¹

¹NC State University Veterinary Hospital, 1052 William Moore Drive, Raleigh, NC, USA
²Veterinary Specialty Services, 1021 Howard George Drive, Manchester, MO, USA
³Cornell University Hospital for Animals Pharmacy, 930 Campus Rd, Ithaca, NY, USA
⁴Duke University, Center for Genomic and Computational Biology, Duke University School of Medicine, 701 W. Main Street, Durham, NC, USA

*Corresponding Author: Early PJ, NC State University Veterinary Hospital, 1052 William Moore Drive, Raleigh, NC, USA.

Received: September 01, 2023; Published: September 12, 2023

Abstract

This study evaluated the pharmacokinetics (PK) of an infusion bolus (IB) of cytarabine (CA) administered subcutaneously (SC) via a novel delivery system (Omnipod®) to dogs with meningoencephalitis of unknown etiology (MUE). Dogs with MUE were enrolled at NC State Veterinary Hospital and received a 75mg/m2 IB SC dose of cytarabine via Omnipod® over 60 minutes. Six dogs were entered into the study, and a total of ten bioavailability profiles were collected. The study design was prospective and non-randomized and used a sparse sampling technique. Plasma CA concentrations were measured by high-pressure liquid chromatography. The mean plasma concentration (Cmax) was 3578 ± 752 ng/mL, the average time to Cmax (Tmax) was 78.89 ± 6.44 minutes. Nonlinear mixed effects modeling was used to obtain population estimates for the absorption rate constant (Ka), clearance per fraction absorbed (Cl/F), and volume of distribution per fraction absorbed (V/F). The mean plasma concentration of CA for all measured time points was above 1000 ng/ml at the 30, 60, 90, 105, 120, 150, 180 and 240-minute time points. Following a single SC IB of 75 mg/m2 of CA in dogs with MUE, the PK of CA was similar to values previously reported in healthy beagles and dogs with MUE when administered via intravenous (IV) and subcutaneous (SC) routes. Therefore, Omnipod® IB may be an effective alternative to CA's traditional injection protocols.

Keywords: Dog; MUE; Cytarabine; Pod; Bolus

References

1. Cuddon PA., et al. “New treatments for granulomatous meningoencephalomyelitis”. Proceedings 20^th ACVIM Forum (2002): 319-321.
2. Scott-Moncrieff JCR., et al. “Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside and dogs”. Cancer Chemotherapy and Pharmacology 29 (1991): 13-18.
3. Menaut P., et al. “Treatment of 11 dogs with meningoencephalomyelitis of unknown origin with a combination of prednisolone and cytosine arabinoside”. The Veterinary Record 162 (2008): 241-245.
4. Behr S., et al. “Treatment of meningoencephalitis of unknown origin in a dog”. Veterinary Record 164 (2009): 627- 629.
5. Lowrie M., et al. “Meningoencephalitis of unknown origin: investigating prognostic factors and outcome using a standard treatment protocol”. Veterinary Record20 (2013): 527.
6. Cornelis I., et al. “Clinical presentation, diagnostic findings, prognostic factors, treatment and outcome in dogs with meningoencephalomyelitis of unknown origin: a review”. Veterinary Journal 244 (2019): 37-44.
7. Lowrie M., et al. “Effect of a constant rate infusion of cytosine arabinoside on mortality in dogs with meningoencephalitis of unknown origin”. The Veterinary Journal 213 (2016): 1-5.
8. Mancini SL., et al. “Novel subcutaneous cytarabine infusion with the Omnipod system in dogs with meningoencephalomyelitis of unknown etiology”. American Journal of Veterinary Research, 83.9 (2022). ajvr.22.03.0046.
9. Crook KI., et al. “The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes”. The Journal of Veterinary Pharmacology and Therapeutics 36 (2012): 408-411.
10. Jones A., et al. “The pharmacokinetics of cytarabine administered at three distinct subcutaneous dosing protocols in dogs with meningoencephalitis of unknown origin”. The Journal of Veterinary Pharmacology and Therapeutics (2019): 1-5.
11. Levitin HA., et al. “Pharmacokinetics of a cytosine arabinoside subcutaneous protocol in dogs with meningoencephalomyelitis of unknown aetiology”. The Journal of Veterinary Pharmacology and Therapeutics 44 (2020): 696-704.
12. Li M., et al. “A framework for meta- analysis of veterinary drug pharmacokinetic data using mixed-effect modeling”. Journal of Pharmaceutical Sciences 4 (2015): 1230-1239.
13. Gabrielsson J and Weiner D. “Parameter Estimation. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, 4^th Stockholm, Sweden: Swedish Pharmaceutical Press (2017).
14. Early PJ., et al. “Plasma and serum concentration of cytarabine administered via continuous intravenous infusion to dogs with meningoencephalomyelitis”. The Journal of Veterinary Pharmacology and Therapeutics 40 (2016): 411- 414.
15. Pastina B., et al. “The pharmacokinetics of cytarabine of cytarabine administered subcutaneously, combined with prednisone, in dogs with meningoencephalomyelitis of unknown etiology”. JVPT (2018).
16. Tse FL and Nedelman JR. “Serial versus sparse sampling in toxicokinetic studies”. Pharmaceutical Research 7 (1996): 1105-1108.
17. Faruqi A and Tadi P. “Cytarabine”. In: StatPearls. Treasure Island (FL): StatPearls Publishin (2022).

Citation

Citation: Early PJ., et al. “Cytarabine Pod Infusion Bolus in Dogs with Meningoencephalitis of Unknown Etiology".Acta Scientific Veterinary Sciences 5.10 (2023): 29-33.

Copyright

Copyright: © 2023 Early PJ., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.